Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

EyePoint Pharmaceuticals (EYPT) Current Deferred Revenue: 2011-2018

Historic Current Deferred Revenue for EyePoint Pharmaceuticals (EYPT) over the last 7 years, with Dec 2018 value amounting to $30,000.

  • EyePoint Pharmaceuticals' Current Deferred Revenue fell 94.06% to $30,000 in Q4 2018 from the same period last year, while for Dec 2018 it was $30,000, marking a year-over-year decrease of 94.06%. This contributed to the annual value of $50,000 for FY2017, which is 65.99% down from last year.
  • EyePoint Pharmaceuticals' Current Deferred Revenue amounted to $30,000 in Q4 2018, which was down 87.50% from $240,000 recorded in Q1 2018.
  • In the past 5 years, EyePoint Pharmaceuticals' Current Deferred Revenue registered a high of $5.6 million during Q3 2014, and its lowest value of $10,000 during Q3 2017.
  • For the 3-year period, EyePoint Pharmaceuticals' Current Deferred Revenue averaged around $153,200, with its median value being $137,500 (2016).
  • As far as peak fluctuations go, EyePoint Pharmaceuticals' Current Deferred Revenue slumped by 99.66% in 2016, and later spiked by 1,247.37% in 2017.
  • Over the past 5 years, EyePoint Pharmaceuticals' Current Deferred Revenue (Quarterly) stood at $5.6 million in 2014, then crashed by 99.50% to $28,000 in 2015, then surged by 385.71% to $136,000 in 2016, then spiked by 271.32% to $505,000 in 2017, then tumbled by 94.06% to $30,000 in 2018.
  • Its Current Deferred Revenue stands at $30,000 for Q4 2018, versus $240,000 for Q1 2018 and $505,000 for Q4 2017.